C Difficile

Delving into the probing, curious question of just how impactful our gut health really is

The resources are available on the ADA’s Oral Health Topics webpage on antibiotic stewardship.

J.P. Morgan has initiated Seres Therapeutics (MCRB) with a neutral rating saying that it will take time for SER-109 to have its reimbursement take place.

Clostridioides difficile infection surveillance in intensive care units and oncology wards using machine learning

A new study shows that the gut microbiota has little or no effect on our weight, metabolism and risk of developing chronic diseases.

NCT04935684.

Those prepared with bacterial cultures may be useful, but scientific support for their alleged benefits in treating diarrhea, eczema, and ear infections is scarce. We review the data

Proton pump inhibitors (PPIs), although introduced 25 years ago, still find their relevance in modern clinical practice settings and have been widely used in the management of acid-peptic...

Small-molecule inhibitors offer many advantages for manipulating the gut microbiome, both as tool compounds and as potential therapeutics. This Review highlights recent examples of inhibitors that target gut bacterial enzymatic activity as well as the challenges and opportunities associated with their design and development.

Eric Shaff is the President and CEO of Seres Therapeutics, which is focused on the gut microbiome in order to develop bacteria as an oral treatment for bloodstream infections, cancer, and immune system diseases. The first therapy is SER-109 for recurrent C. diff infection an orphan disease with inadequate solutions for patients. The starting point for Seres is that the health of the microbiome is the starting point for preventing infections from occurring. Eric explains, "The real susceptibility of someone getting C. diff is not just the bad actor bacteria. But really the susceptibility of the microbiome and an injury to the microbiome, and susceptibility to infection. Typically what happens is if people get antibiotic therapy, which can be very effective in knocking back or killing all bacteria, it creates a significant niche in the microbiome, or an injury. There is what we call a race to repair, so either a patient will naturally repair and restore their microbiome, or C. diff may infiltrate, which can lead to an infection and a recurrence." "Typically, if a patient is going to have a recurrence, it happens quickly. If they get C. diff, they take antibiotics, and the hope is that C. diff will not infiltrate to cause an occurrence. If it does, then people typically recur quickly. What happens following antibiotic therapy, is we treat patients with an oral regimen of SER-109, which is a consortium of bacteria in spore form you put in the capsule. That was the approach we took to our phase 3 study, where we had an 88% reduction in recurrence, which is a significant impact for patients suffering from this terrible disease." @SeresTX #SeresTherapeutics #Microbiome #OralMicrobiomeTherapy #Cdiff #RecurrentCdiff #AMR #AntimicrobialResistance #InfectionProtection

Intestinal bile acids play an essential role in the Clostridioides difficile lifecycle having been shown in vitro to modulate various aspects of pathogenesis, including spore germination, vegetative growth, and more recently the action of the primary virulence determinant, TcdB. Here, we inve …

Clostridioides difficile (C. difficile) and coronavirus disease 2019 (COVID-19) infections can have overlapping symptoms. Recently, the association and outcomes of coinfection have been studied....

Clostridioides difficile, the primary cause of nosocomial antibiotic-associated diarrhea, has a complex relationship with antibiotics. While the use of broad-spectrum antibiotics disrupts the gut microbiota and increases the risk of C. difficile infection (CDI), antibiotics are also the primary trea …

Co-existing CMV colitis should be considered in patients with aggravated C. difficile infection on appropriate treatment, even in immunocompetent hosts.

We observed differences in microbiome patterns between healthy individuals, colonized patients, CDI, R-CDI, and NOCDI diarrhea. We identified possible microbiome biomarkers that could prove useful in the diagnosis of true CDI infections. Further studies are warranted.

Tumor immune microenvironment (TIME), a tumor-derived immune component, is proven to be closely related to the development, metastasis, and recurrence of tumors. Gut microbiota and its fermented-metabolites short-chain fatty acids (SCFAs) play a critical role in maintaining the immune homeostasis of …

Collectively, our findings demonstrate that the gut microbiota in lactating mastitis patients is dysbiotic and contributes to the pathogenesis of mastitis.

The gut microbiome is critically involved in maintaining normal physiological function in the host. Recent studies have revealed that alterations in the gut microbiome contribute to the development and progression of cerebrovascular disease via the microbiota-gut-brain axis (MGBA). As a broad …

Co-existing CMV colitis should be considered in patients with aggravated C. difficile infection on appropriate treatment, even in immunocompetent hosts.

We observed differences in microbiome patterns between healthy individuals, colonized patients, CDI, R-CDI, and NOCDI diarrhea. We identified possible microbiome biomarkers that could prove useful in the diagnosis of true CDI infections. Further studies are warranted.

Educational Case: Pseudomembranous colitis attributable to Clostridioides difficile

Peripartum CDI was associated with higher odds of cesarean delivery and lower odds of GBS infections. Larger studies exploring the effect of CDI on pregnancy and neonatal outcomes are needed.

Understanding the physiological origins of age-related cognitive decline is of critical importance given the rising age of the world's population1. Previous work in animal models has established a strong link between cognitive performance and the microbiota2-5, and it is known …

The gut microbiota is increasingly recognized as an important regulator of host immunity and brain health. The aging process yields dramatic alterations in the microbiota, which is linked to poorer health and frailty in elderly populations. However, there is limited evidence for a mechanistic role o …

Both genetic susceptibility and environmental factors are important contributors to autoimmune disease pathogenesis. As an environmental factor, the gut microbiome plays a crucial role in the development and progression of autoimmune diseases. Thus, strategies targeting gut microbiome alterations ca …

Bacterial spores can survive for years, even centuries, without nutrients, resisting heat, UV radiation, and antibiotics. How inert, sleeping bacteria -- or spores -- spring back to life has been a century-long mystery. New research identifies how sensor proteins revive dormant bacteria. Discovery opens new routes to combat spore resistance to antibiotics and sterilization. Findings can inform novel strategies to prevent infections, food spoilage.

The newly-predominant RT176 and endemic RT001 drive CDI epidemiology in Slovakia. In addition to fluoroquinolones, the use of macrolide-lincosamide-streptogramin B group of antibiotics can represent another driving force for the spread of these epidemic lineages. In C. difficile, linezolid resistanc …

Both genetic susceptibility and environmental factors are important contributors to autoimmune disease pathogenesis. As an environmental factor, the gut microbiome plays a crucial role in the development and progression of autoimmune diseases. Thus, strategies targeting gut microbiome alterations ca …

“Can confirm the herculean effort of Dr. Rashidi and CRC Andrea @amfhoeschen in completing the #FMT prophylaxis study at @umnmedschool. 💪 IIT 🚫 industry support. Valuable study, much learned, excellent effort to move the 🦠💩field forward. #MSKTOXTCT”

RBX2660 and Vowst are now both approved for the prevention of recurrent C. difficile infections.